ATE Insider Trading

Insider Ownership Percentage: 7.79%
Insider Buying (Last 12 Months): C$46,300.00
Insider Selling (Last 12 Months): C$16,430.00

Antibe Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Antibe Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Antibe Therapeutics Share Price & Price History

Current Price: C$0.60
Price Change: Price Increase of +0.04 (7.14%)
As of 03/22/2023 01:00 AM ET

This chart shows the closing price history over time for ATE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Antibe Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2022Daniel Marcel LegaultDirectorBuy40,000C$0.49C$19,400.00983,296
11/15/2022Scott Wilson CurtisSenior OfficerBuy20,000C$0.50C$10,000.00100,000
7/15/2022John Lawrence WallaceDirectorSell5,000C$0.62C$3,100.001,772,976
7/11/2022Daniel Marcel LegaultDirectorBuy7,500C$0.60C$4,500.00888,796
7/8/2022Scott Wilson CurtisSenior OfficerBuy20,000C$0.62C$12,400.0080,000
7/7/2022John Lawrence WallaceDirectorSell21,500C$0.62C$13,330.001,899,576
11/10/2021Walter Minnes MacneeDirectorBuy50,000C$0.90C$45,000.00497,027
11/3/2021Walter Minnes MacneeDirectorBuy25,000C$0.98C$24,385.00447,027
11/1/2021Daniel Marcel LegaultDirectorBuy2,500C$0.92C$2,300.00778,796
11/1/2021Scott Wilson CurtisSenior OfficerBuy13,000C$0.88C$11,440.0060,000
8/4/2021Daniel Marcel LegaultDirectorBuy12,500C$1.02C$12,750.00776,296
7/14/2021Scott Wilson CurtisSenior OfficerBuy2,600C$3.42C$8,892.0037,000
7/13/2021Daniel Marcel LegaultDirectorBuy4,000C$3.57C$14,280.00763,796
6/30/2021Daniel Marcel LegaultDirectorBuy4,000C$3.70C$14,800.00759,796
6/3/2021Daniel Marcel LegaultDirectorSell75,000C$4.00C$300,300.00755,796
9/24/2020Daniel Marcel LegaultDirectorBuy75,000C$0.34C$25,500.00375,000
9/24/2020David James VaughanSenior OfficerBuy52,500C$0.34C$17,850.0052,500
9/22/2020John Lawrence WallaceDirectorBuy71,500C$0.37C$26,455.00348,270
9/21/2020Scott Wilson CurtisSenior OfficerBuy30,000C$0.35C$10,500.00309,000
6/3/2020Daniel Marcel LegaultDirectorSell259,500C$0.61C$156,997.50525,000
6/3/2020Scott Wilson CurtisSenior OfficerSell24,000C$0.61C$14,640.00246,000
6/1/2020Daniel Marcel LegaultDirectorSell1,250,000C$0.61C$762,500.00800,000
6/1/2020David James VaughanSenior OfficerSell150,000C$0.60C$90,000.0055,000
See Full Table

SEC Filings (Institutional Ownership Changes) for Antibe Therapeutics (TSE:ATE)

Antibe Therapeutics logo
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.
Read More on Antibe Therapeutics

Today's Range

Now: C$0.60
Low: C$0.56
High: C$0.65

50 Day Range

MA: C$0.57
Low: C$0.48
High: C$0.69

52 Week Range

Now: C$0.60
Low: C$0.41
High: C$0.83


185,992 shs

Average Volume

39,629 shs

Market Capitalization

C$31.48 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Antibe Therapeutics?

Antibe Therapeutics' top insider investors include:
  1. John Lawrence Wallace (Director)
  2. Daniel Marcel Legault (Director)
  3. Walter Minnes Macnee (Director)
  4. Scott Wilson Curtis (Senior Officer)
Learn More about top insider investors at Antibe Therapeutics.